Bolt Biotherapeutics Amends Lease, Pays $1M and Faces $4.5M Termination Payment
BOLT is trading near its 52-week low of $3.1 (13% above the low).
Summary
Bolt Biotherapeutics amended its Redwood City lease, paying $1M upfront and agreeing to a $4.5M termination payment if a Corporate Transaction closes, while accelerating lease expiration to December 31, 2027.
Key Events · Financing and Capital Events · BOLT
-
Lease Amendment Signed
On October 1, 2026, Bolt entered into a Second Amendment to Lease with HCP LS Redwood City LLC for its Redwood City facilities.
-
Upfront Cash Outflow
Company paid $1.0 million to the landlord and acknowledged the landlord's right to draw the existing $1.5 million letter of credit in full.
-
Accelerated Expiration and Termination Payment
Lease expiration accelerated to December 31, 2027, or earlier upon a Corporate Transaction, which would trigger an additional $4.5 million termination payment.
-
Reduced Ongoing Rent
Effective October 1, 2026, ongoing rent and operating expense obligations for the Premises are not significant, with sublease rent remitted 100% to landlord.
Analysis · BOLT · Life Sciences
Bolt Biotherapeutics entered into a Second Amendment to its Chesapeake Master Lease on October 1, 2026, paying $1.0 million upfront and allowing the landlord to draw the full $1.5 million letter of credit. The lease now expires December 31, 2027, or earlier upon a Corporate Transaction, which would trigger an additional $4.5 million termination payment. This is material because the company had only $18.1 million in cash as of Q2 2026 and management warned it may not survive beyond Q1 2027 without new funding. The lease amendment reduces future rent obligations but locks in up to $7.0 million in near-term cash outflows, further straining liquidity.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.5% of the 1494 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BOLT was trading at $3.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $3.10 to $7.20. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.